Abstract: The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

Abstract: The present disclosure relates to a vehicle exhaust assembly (1) for an internal combustion engine. The vehicle exhaust assembly (1) comprises an exhaust system (3) and an exhaust mounting assembly (4) for mounting the exhaust system (3) to a vehicle (2). The exhaust system (3) comprises an inlet section (5) for connection to the internal combustion engine; an intermediate section (6) connected to the inlet section (5); an outlet section (7) for exhausting gases from the internal combustion engine; and one or more exhaust decoupler (8) for decoupling the intermediate section (6) from the inlet section (5). The exhaust mounting assembly (4) comprises one or more first isolator device (20-1, 20-2) for resiliently constraining movement of the intermediate section (6) of the exhaust system (3) in a longitudinal direction; and one or more second isolator device (20-3, 20-4) for resiliently constraining movement of the outlet section (7) of the vehicle (2) exhaust in a transverse direction.

Abstract: Aspects of the present invention relate to an active noise system (4), a vehicle (1) with an active noise system (4), a method for controlling an active noise system (4), a computer program for controlling an active noise system (4) and an active noise controller (40). The wading detection system (3) includes sensors (30, 31, 32, 33) for detecting a wading depth and a wading detection controller (34). The active noise system (4) includes speakers (41, 42) for modifying the exhaust noise emitted from the vehicle (1). The wading detection controller (34) is operable to detect or anticipate a predetermined wading depth (W1, W2) at which the speakers (41, 42) will come into contact with the water. The active noise controller (40) is configured to deactivate the speakers (41, 42) when the predetermined wading depth (W1, W2) is detected or anticipated by the wading detection controller (34).

Abstract: Aspects of the present invention relate to noise modification systems of motor vehicles, and controllers and methods of use thereof.

Abstract: The present disclosure relates to a vehicle exhaust assembly (1) for an internal combustion engine. The vehicle exhaust assembly (1) comprises an exhaust system (3) and an exhaust mounting assembly (4) for mounting the exhaust system (3) to a vehicle (2). The exhaust system (3) comprises an inlet section (5) for connection to the internal combustion engine; an intermediate section (6) connected to the inlet section (5); an outlet section (7) for exhausting gases from the internal combustion engine; and one or more exhaust decoupler (8) for decoupling the intermediate section (6) from the inlet section (5). The exhaust mounting assembly (4) comprises one or more first isolator device (20-1, 20-2) for resiliently constraining movement of the intermediate section (6) of the exhaust system (3) in a longitudinal direction; and one or more second isolator device (20-3, 20-4) for resiliently constraining movement of the outlet section (7) of the vehicle (2) exhaust in a transverse direction.

Abstract: Aspects of the present invention relate to an active noise system, a controller for an active noise system, a method and a hybrid electric vehicle. The invention relates to use of an active noise system for providing noise when an ICE is not active.

Abstract: Aspects of the present invention relate to an active noise system (4), a vehicle (1) with an active noise system (4), a method for controlling an active noise system (4), a computer program for controlling an active noise system (4) and an active noise controller (40). The wading detection system (3) includes sensors (30, 31, 32, 33) for detecting a wading depth and a wading detection controller (34). The active noise system (4) includes speakers (41, 42) for modifying the exhaust noise emitted from the vehicle (1). The wading detection controller (34) is operable to detect or anticipate a predetermined wading depth (W1, W2) at which the speakers (41, 42) will come into contact with the water. The active noise controller (40) is configured to deactivate the speakers (41, when the predetermined wading depth (W1, W2) is detected or anticipated by the wading detection controller (34).

Abstract: Aspects of the present invention relate to noise modification systems of motor vehicles, and controllers and methods of use thereof.

Abstract: Aspects of the present invention relate to an active noise system, a controller for an active noise system, a method and a hybrid electric vehicle. The invention relates to use of an active noise system for providing noise when an ICE is not active.

Abstract: The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: 5-amino-3-(2?-O-acetyl-3?-deoxy-?-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one Tosylate according to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.

Abstract: The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: 5-amino-3-(2?-O-acetyl-3?-deoxy-?-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one Tosylate according to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.

Abstract: The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: Formula (I) 5-amino-3-(2?-Q-acetyl-3?-deoxy-?-D-ri-bofuranosyl)-3H-thia-zolo[4,5-d]pyrimidin-2-one Tosylate according to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.